Tag «anax labs»

Pasodacigib

Pasodacigib Cas 2648721-77-9 MFC24H23FN4O3 mw 434.5 g/mol 3-Quinolinecarboxamide, 6-fluoro-1,2-dihydro-1-methyl-4-[4-(5-methyl-2-benzoxazolyl)-1-piperidinyl]-2-oxo- 6-fluoro-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide 6-fluoro-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamidediacylglycerol kinase inhibitor, antineoplastic, BAY 2862789, BAY-2862789, XM6U88YE6H Pasodacigib (also known by its developmental code BAY 2862789 or BAY-2862789) is an investigational small-molecule drug developed by Bayer AG. It functions as a potent and selective diacylglycerol kinase alpha (DGKα) inhibitor designed for cancer immunotherapy. 🧪 Mechanism …

Pariceract

Pariceract CAS 1919820-28-2 MFC20H30N4O2 MW358.5 g/mol 5,7-dimethyl-N-[trans-4-(pentyloxy)cyclohexyl]pyrazolo[1,5-a]pyrimidine-3-carboxamidebeta-glucocerebrosidase activator, antiparkinsonian, BIA 28-6156, LTI-291, LIT291, LTI-00291, BIA28-6156, LTI- 91, LIT 291, LTI 00291, Gcase activator 1, V9WUN9UUU8 Pariceract (INNTooltip International Nonproprietary Name; developmental code name BIA 28-6156 or LTI-291) is a β-glucocerebrosidase (GCase) activator or positive allosteric modulator which is under development for the treatment of Parkinson’s disease.[1][2][3][4][5] It is taken orally.[1] GCase is a lysosomal enzyme encoded by the gene GBA1.[4][5] Loss-of-function mutations in this gene are thought to …

Palacaparib

Palacaparib CAS 2756333-39-6 MFC21H22F2N6O2 MW428.4 g/mol 6-fluoro-5-[4-[(5-fluoro-2-methyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N-methylpyridine-2-carboxamide 2-Pyridinecarboxamide, 6-fluoro-5-(4-((5-fluoro-3,4-dihydro-2-methyl-3-oxo-6-quinoxalinyl)methyl)-1-piperazinyl)-N-methyl- 6-fluoro-5-{4-[(5-fluoro-2-methyl-3-oxo-3,4-dihydroquinoxalin-6-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamidepoly (ADP-ribose) polymerase (PARP) inhibitor, antineoplastic, AZD 9574, 9UG32UQW48 Palacaparib is an investigational new drug that is being evaluated by AstraZeneca for the treatment of prostate cancer.[1] It is a selective PARP1 inhibitor.[2][3] Palacaparib (also known as AZD9574) is an investigational, orally bioavailable cancer drug developed by AstraZeneca. It belongs to a class of medications called …

Zidesamtinib

Zidesamtinib CAS 2739829-00-4 MF C22H22FN7O MW419.5 g/mol (19R)-3-ethyl-16-fluoro-10,19-dimethyl-20-oxa-3,4,9,10,11,23-hexazapentacyclo[19.3.1.02,6.08,12.013,18]pentacosa-1(25),2(6),4,8,11,13(18),14,16,21,23-decaen-22-amine To treat adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer after receiving a ROS1 kinase inhibitor FDA 2026, APPROVALS 2026, Jideytro, NVL-520, NUV-520, NU-520, NVL 520, NUV 520, NU 520, MX5KQV5XHC Zidesamtinib (sold under the brand name Jideytro) is an oral, highly selective, next-generation kinase …

Gedatolisib

Gedatolisib Approvals 3026, FDA 2026, 7/14/2026, Revtorpyk PF-05212384; PF-5212384; PKI-587CAS 1197160-78-3Chemical Formula: C32H41N9O4Molecular Weight: 615.721-(4-{[4-(Dimethylamino)-1-piperidinyl]carbonyl}phenyl)-3-{4-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]phenyl}urea3-{4-[bis(morpholin-4-yl)-1,3,5-triazin-2-yl]phenyl}-1-{4-[4-(dimethylamino)piperidine-1-carbonyl]phenyl}ureaN-[4-[[4-(Dimethylamino)-1-piperidinyl]carbonyl]phenyl]-N’-[4-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]phenyl]ureaгедатолисиб [Russian] [INN]غيداتوليسيب [Arabic] [INN]吉达利塞 [Chinese] [INN] 1-(4-(4-(Dimethylamino)piperidine-1-carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)urea Urea, N-[4-[[4-(dimethylamino)-1-piperidinyl]carbonyl]phenyl]-N’-[4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)phenyl]- 96265TNH2R In combination with fulvestran, to treat hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line …

Opakalim

Opakalim CAS 2376397-93-0 MF C18H22F2N4O MW 348.4 g/mol N-(1-tert-butyl-6-cyano-4,7-difluorobenzimidazol-2-yl)-3,3-dimethylbutanamide N-(1-tert-butyl-6-cyano-4,7-difluoro-1H-1,3-benzimidazol-2-yl)-3,3-dimethylbutanamidepotassium channel activator, antiepileptic, BHV-7000; BHV7 000, BPN-25203, BPN 25203, KB-3061, KB 3061, 73H9J7RBA2 BHV-7000 is under investigation in clinical trial NCT06419608 (Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression). Opakalim (also known as BHV-7000) is an investigational, small-molecule medication that acts as a selective …

Ontunisertib

Ontunisertib CAS 2647949-48-0 MFC27H21F2N5O MW469.5 g/mol N-[(2,6-difluorophenyl)methyl]-2-[3-(6-methyl-2-pyridinyl)-4-quinolin-4-ylpyrazol-1-yl]acetamide N-(2,6-difluorobenzyl)-2-(3-(6-methylpyridin-2-yl)-4-(quinolin-4-yl)-1H-pyrazol-1-yl)acetamide N-[(2,6-difluorophenyl)methyl]-2-[3-(6-methylpyridin-2-yl)-4-(quinolin-4-yl)-1H-pyrazol-1-yl]acetamideserine/threonine kinase inhibitor, AGMB 129, SF6HGC94LK Ontunisertib (AGMB-129) is an experimental, orally active small-molecule drug developed by Agomab Therapeutics to treat Fibrostenosing Crohn’s Disease (FSCD). It acts as a highly selective inhibitor of ALK5 (also known as Transforming Growth Factor-beta type I receptor or TGF-β RI). Mechanism of …

Olisutrigine bromide

Olisutrigine bromide Cas 1393836-45-7 MF C25H35BrN2 MW443.5 g/mol N-[2-[(2R)-1,1-dimethylpiperidin-1-ium-2-yl]ethyl]-N-(2-methylphenyl)-2,3-dihydro-1H-inden-2-amine bromide (2R)-2-{2-[N-(2,3-dihydro-1H-inden-2-yl)-2-methylanilino]ethyl}-1,1-dimethylpiperidin-1-ium bromidesodium channel blocker, analgesic, ASN008, ASN 008, EN 3427, 0M9Q318030 Olisutrigine bromide (also known as ASN-008 or EN3427) is an investigational, permanently charged sodium channel blocker being studied for its potent, long-lasting analgesic (pain-relieving) properties. Key Characteristics Current Status A Study to Evaluate the Anti-pruritic …

Netanasvir

Netanasvir CAS 2007900-70-9 MF C51H58N8O7 MW895.1 g/mol methyl N-[(1R)-2-[(2S,4S)-2-[5-[7-[2-[(2S,5S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]-5-methylpyrrolidin-2-yl]-3H-benzo[e]benzimidazol-7-yl]-2,3-dihydro-1H-inden-4-yl]-1H-imidazol-2-yl]-4-(methoxymethyl)pyrrolidin-1-yl]-2-oxo-1-phenylethyl]carbamate antiviral, Dongweizhuo, HCV, Antaitavir Hasophate, HEC 74647 PA, 4Y7YD32BYY Netanasvir (commonly prescribed as netanasvir phosphate) is a direct-acting antiviral medication primarily used to treat chronic hepatitis C virus (HCV) infection. It was approved by the China National Medical Products Administration (NMPA) under the trade name Dongweizhuo. Key Clinical …